tiprankstipranks
BridgeBio Pharma Reports Quarterly Loss Amid Restructuring
PremiumCompany AnnouncementsBridgeBio Pharma Reports Quarterly Loss Amid Restructuring
9d ago
BridgeBio reports Q3 EPS (86c), consensus (98c)
Premium
The Fly
BridgeBio reports Q3 EPS (86c), consensus (98c)
11d ago
BridgeBio announces publication on impact of biomedical innovation
Premium
The Fly
BridgeBio announces publication on impact of biomedical innovation
18d ago
BridgeBio initiated with an Outperform at Scotiabank
PremiumThe FlyBridgeBio initiated with an Outperform at Scotiabank
1M ago
BridgeBio Pharma call volume above normal and directionally bullish
Premium
The Fly
BridgeBio Pharma call volume above normal and directionally bullish
1M ago
BridgeBio presenting results of Phase 3 study of acoramidis in ATTR-CM
Premium
The Fly
BridgeBio presenting results of Phase 3 study of acoramidis in ATTR-CM
2M ago
BioMarin price target lowered to $90 from $118 at Truist
PremiumThe FlyBioMarin price target lowered to $90 from $118 at Truist
2M ago
BridgeBio announces FDA granted BTD to oral infigratinib
Premium
The Fly
BridgeBio announces FDA granted BTD to oral infigratinib
2M ago
BioMarin price target lowered to $115 from $130 at BofA
Premium
The Fly
BioMarin price target lowered to $115 from $130 at BofA
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100